Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6889450 single- and multiple-ascending dose study in healthy volunteers
NL-OMON44416Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of ralmitaront in schizophrenia and bipolar disorder (BD) (12 cohorts), sponsored by Roche. Started Mar 2016; status: active, not recruiting.
02
Drugs
ralmitaront
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NL-OMON44416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44416.